Sandoz Application for proposed biosimilar adalimumab’s high concentration formulation accepted by EMA
The Pharma Data
JUNE 17, 2022
“By committing to bring biosimilar formulations such as Hyrimoz citrate-free HCF to patients, we are serving a critical need in expanding access to important medicines and fueling pharmaceutical innovation.”. About adalimumab Adalimumab is a human immunoglobulin G1 (IgG(1)) monoclonal antibody targeting tumor necrosis factor alpha (TNF-a).
Let's personalize your content